{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:54:32Z","timestamp":1790621672125,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.anai.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:36:47Z","timestamp":1743352607000},"page":"103-111.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults"],"prefix":"10.1016","volume":"135","author":[{"given":"William","family":"Lumry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jou-Ku","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.anai.2025.03.016_bib0001","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2025.03.016_bib0002","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","article-title":"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review","volume":"19","author":"Guan","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.anai.2025.03.016_bib0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.03.016_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fmed.2018.00022","article-title":"Hereditary angioedema: the economics of treatment of an orphan disease","volume":"5","author":"Lumry","year":"2018","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.anai.2025.03.016_bib0005","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1016\/j.jaip.2021.08.019","article-title":"Racial and ethnic disparities in the research and care of hereditary angioedema patients in the United States","volume":"9","author":"Sylvestre","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.03.016_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12135","article-title":"Comorbidities in hereditary angioedema\u2014a population-based cohort study","volume":"12","author":"Sundler Bj\u00f6rkman","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"3","key":"10.1016\/j.anai.2025.03.016_bib0007","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary angioedema: diagnosis, clinical implications, and pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.anai.2025.03.016_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1263432","article-title":"Pathophysiology of bradykinin and histamine mediated angioedema","volume":"4","author":"Lima","year":"2023","journal-title":"Front Allergy"},{"issue":"5 suppl 1","key":"10.1016\/j.anai.2025.03.016_bib0009","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.anai.2023.08.099","article-title":"Bradykinin measurement by mass-spectrometry correlates with angioedema attack frequency in bradykinin-mediated angioedema","volume":"131","author":"Li","year":"2023","journal-title":"Ann Allergy Immunol"},{"issue":"3 suppl","key":"10.1016\/j.anai.2025.03.016_bib0010","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1186\/1939-4551-3-S3-S34","article-title":"Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism","volume":"3","author":"Riedl","year":"2010","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.anai.2025.03.016_bib0011","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jaip.2021.11.011","article-title":"Specific targeting of plasma kallikrein for treatment of hereditary angioedema: a revolutionary decade","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2025.03.016_bib0012","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2025.03.016_bib0013","unstructured":"Zuraw B.L., on behalf of US HAEA Medical Advisory Board. \u201cLetter to Robert M. Califf, MD, MACC.\u201d July 19, 2024. Personal correspondence from the US HAEA Med Advisory Board. Accessed September 25, 2024."},{"issue":"6","key":"10.1016\/j.anai.2025.03.016_bib0014","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.03.016_bib0015","doi-asserted-by":"crossref","first-page":"AB21","DOI":"10.1016\/j.jaci.2020.12.115","article-title":"Despite prophylactic treatments, break-through attacks continue among patients with hereditary angioedema","volume":"147","author":"Radojicic","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.03.016_bib0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.03.016_bib0017","unstructured":"Takeda Pharmaceuticals USA, Inc. CINRYZE (C1 esterase inhibitor [human]) for intravenous use. Accessed August 7, 2024. Available at: https:\/\/pi.shirecontent.com\/PI\/PDFs\/Cinryze_USA_ENG.pdf"},{"issue":"3","key":"10.1016\/j.anai.2025.03.016_bib0018","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"10.1016\/j.anai.2025.03.016_bib0019","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.123.001740","article-title":"STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma kallikrein for the potential treatment of hereditary angioedema","volume":"387","author":"Bedian","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.anai.2025.03.016_bib0020","unstructured":"Astria Therapetics, Inc. Astria corporate update. Accessed October 10, 2024. Available at: https:\/\/ir.astriatx.com\/static-files\/52767c7c-33e4-40cf-9d3c-090db659c01e."},{"issue":"20","key":"10.1016\/j.anai.2025.03.016_bib0021","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2025.03.016_bib0022","unstructured":"Takeda Pharmaceutical Company Limited. KALBITOR (ecallantide) injection, for subcutaneous use. Accessed August 10, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125277s081lbl.pdf"},{"key":"10.1016\/j.anai.2025.03.016_bib0023","unstructured":"Takeda Pharmaceutical Company Limited. TAKHZYRO (lanadelumab-flyo) injection, for subcutaneous use. Accessed August 10, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761090s010lbl.pdf"},{"issue":"12","key":"10.1016\/j.anai.2025.03.016_bib0024","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/blood.V77.12.2660.2660","article-title":"Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis","volume":"77","author":"Kaufman","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2025.03.016_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1586\/eci.11.81","article-title":"Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema","volume":"8","author":"Stolz","year":"2012","journal-title":"Exp Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.03.016_bib0026","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/cts.12806","article-title":"Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema","volume":"13","author":"Wang","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.anai.2025.03.016_bib0027","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","article-title":"A phase 1 study investigating DX-2930 in healthy subjects","volume":"113","author":"Chyung","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.03.016_bib0028","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/cea.12293","article-title":"High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency","volume":"44","author":"Suffritti","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2025.03.016_bib0029","unstructured":"BioCryst Pharmaceuticals, Inc. ORLADEYO (berotralstat) capsules, for oral use. Accessed August 10, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214094s002lbl.pdf"},{"key":"10.1016\/j.anai.2025.03.016_bib0030","series-title":"HAEGARDA\u00ae (C1 esterase inhibitor subcutaneous [human])","year":"2022"},{"issue":"10382","key":"10.1016\/j.anai.2025.03.016_bib0031","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2025.03.016_bib0032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"issue":"388","key":"10.1016\/j.anai.2025.03.016_bib0033","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anai.2025.03.016_bib0034","unstructured":"United States Food and Drug Administration. FDA approves new drug to prevent RSV in babies and toddlers. Accessed August 8, 2024. Available at:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers"},{"key":"10.1016\/j.anai.2025.03.016_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.03.016_bib0036","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.anai.2025.03.016_bib0037","unstructured":"AstraZeneca. BEYFORTUS (nirsevimab-alip) injection, for intramuscular use. Accessed October 29, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761328s005lbl.pdf"},{"key":"10.1016\/j.anai.2025.03.016_bib0038","unstructured":"ClinicalTrials.gov. A study of STAR-0215 in participants with hereditary angioedema. Accessed August 10, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05695248"},{"issue":"6","key":"10.1016\/j.anai.2025.03.016_bib0039","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.anai.2024.08.107","article-title":"STAR-0215 induces rapid improvements of quality of life in HAE patients in the ALPHA-STAR trial","volume":"133","author":"Banerji","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2025.03.016_bib0040","unstructured":"ClinicalTrials.gov. A long-term study of STAR-0215 in participants with hereditary angioedema. Accessed August 11, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06007677"},{"key":"10.1016\/j.anai.2025.03.016_bib0041","unstructured":"Astria Therapeutics, Inc. Astria Therapeutics announces design of ALPHA-ORBIT pivotal phase 3 trial of navenibart in HAE. Accessed February 3, 2025. Available at:https:\/\/ir.astriatx.com\/news-releases\/news-release-details\/astria-therapeutics-announces-design-alpha-orbit-pivotal-phase-3"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062500153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062500153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:34:34Z","timestamp":1762364074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062500153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S108112062500153X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.03.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}